Century Therapeutics (IPSC) Cash from Investing Activities (2020 - 2026)

Century Therapeutics (IPSC) has reported Cash from Investing Activities for 7 consecutive years, with -$112.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 503.2% year-over-year to -$112.6 million; the TTM figure through Mar 2026 stood at -$33.0 million (down 151.74% YoY), while the FY2025 annual figure was $107.5 million, up 126.4% from the prior year.
• Cash from Investing Activities slipped to -$112.6 million in Q1 2026 per IPSC's latest filing, from $22.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $39.2 million in Q3 2024 and bottomed at -$112.6 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged $5.3 million across 5 years, with a median of $18.6 million in 2023.
• On a YoY basis, Cash from Investing Activities climbed as much as 829.55% in 2024 and fell as far as 585.57% in 2024.
• Century Therapeutics' Cash from Investing Activities stood at -$4.3 million in 2022, then surged by 535.36% to $18.6 million in 2023, then jumped by 64.52% to $30.6 million in 2024, then declined by 26.94% to $22.4 million in 2025, then slumped by 603.62% to -$112.6 million in 2026.
• Business Quant data shows IPSC's Cash from Investing Activities at -$112.6 million in Q1 2026, $22.4 million in Q4 2025, and $24.7 million in Q3 2025.